BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers 2017;3:17028. [PMID: 28516949 DOI: 10.1038/nrdp.2017.28] [Cited by in Crossref: 145] [Cited by in F6Publishing: 125] [Article Influence: 29.0] [Reference Citation Analysis]
Number Citing Articles
1 Clemente MJ, Przychodzen B, Hirsch CM, Nagata Y, Bat T, Wlodarski MW, Radivoyevitch T, Makishima H, Maciejewski JP. Clonal PIGA mosaicism and dynamics in paroxysmal nocturnal hemoglobinuria. Leukemia 2018;32:2507-11. [PMID: 29749402 DOI: 10.1038/s41375-018-0138-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
2 Chen Y, Liu H, Zeng L, Li L, Lu D, Liu Z, Fu R. A Pig-a conditional knock-out mice model mediated by Vav-iCre: stable GPI-deficient and mild hemolysis. Exp Hematol Oncol 2022;11:1. [PMID: 35033195 DOI: 10.1186/s40164-022-00254-5] [Reference Citation Analysis]
3 Ebo DG. Highlights - June 2017. Cytometry B Clin Cytom 2017;92:247-8. [PMID: 28556550 DOI: 10.1002/cyto.b.21534] [Reference Citation Analysis]
4 Revollo JR, Dad A, Pearce MG, Mittelstaedt RA, Casildo A, Lapidus RG, Robison TW, Dobrovolsky VN. CD59-deficient bone marrow erythroid cells from rats treated with procarbazine and propyl-nitrosourea have mutations in the Pig-a gene. Environ Mol Mutagen 2020;61:797-806. [PMID: 32729949 DOI: 10.1002/em.22402] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Zhou S, Dong X, Chen C, Ma L, Wu Y, Zhou Y, Cui Y. Efficacy and Safety of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Meta-Analysis. J Pediatr Hematol Oncol 2021;43:203-10. [PMID: 33902068 DOI: 10.1097/MPH.0000000000002178] [Reference Citation Analysis]
6 Hanmantgad M, Nog R, Seiter K. Acute myeloid leukemia and fatal Scedosporium prolificans sepsis after eculizumab treatment for paroxysmal nocturnal hemoglobinuria: a case report. Stem Cell Investig 2017;4:100. [PMID: 29359139 DOI: 10.21037/sci.2017.12.04] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
7 DeZern AE, Jones RJ, Brodsky RA. Eculizumab Bridging before Bone Marrow Transplant for Marrow Failure Disorders Is Safe and Does Not Limit Engraftment. Biol Blood Marrow Transplant 2018;24:e26-30. [PMID: 30055352 DOI: 10.1016/j.bbmt.2018.07.032] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
8 Alashkar F, Rottinghaus S, Vance C, Herich-Terhürne D, Dührsen U, Assert R, Röth A. No evidence for hypogammaglobulinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with ravulizumab. PLoS One 2020;15:e0230869. [PMID: 32218584 DOI: 10.1371/journal.pone.0230869] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Zhang L, Dai Y, Huang P, Saunders TL, Fox DA, Xu J, Lin F. Absence of complement component 3 does not prevent classical pathway-mediated hemolysis. Blood Adv 2019;3:1808-14. [PMID: 31196848 DOI: 10.1182/bloodadvances.2019031591] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Pedersen H, Jensen RK, Hansen AG, Gadeberg TAF, Thiel S, Laursen NS, Andersen GR. A C3-specific nanobody that blocks all three activation pathways in the human and murine complement system. J Biol Chem 2020;295:8746-58. [PMID: 32376685 DOI: 10.1074/jbc.RA119.012339] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
11 Delafontaine M, Villas-Boas IM, Pidde G, van den Berg CW, Mathieu L, Blomet J, Tambourgi DV. Venom from Bothrops lanceolatus, a Snake Species Native to Martinique, Potently Activates the Complement System. J Immunol Res 2018;2018:3462136. [PMID: 30116749 DOI: 10.1155/2018/3462136] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
12 Wu Y, Ji Y, Dai B, Guo F, Wu Y, He Z, Mo C, Wu S, Hu Y. A case of hyperhaemolysis syndrome in a pregnant Chinese woman with β-thalassemia during perinatal transfusion. Transfus Med 2021;31:24-9. [PMID: 33331032 DOI: 10.1111/tme.12748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Colden MA, Kumar S, Munkhbileg B, Babushok DV. Insights Into the Emergence of Paroxysmal Nocturnal Hemoglobinuria. Front Immunol 2022;12:830172. [DOI: 10.3389/fimmu.2021.830172] [Reference Citation Analysis]
14 Cheng WY, Sarda SP, Mody-patel N, Krishnan S, Yenikomshian M, Kunzweiler C, Vu JD, Cheung HC, Duh MS. Real-World Eculizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population. CEOR 2022;Volume 14:357-69. [DOI: 10.2147/ceor.s346816] [Reference Citation Analysis]
15 Fu R. [How I diagnose and treat paroxysmal nocturnal hemoglobinuria]. Zhonghua Xue Ye Xue Za Zhi 2018;39:887-91. [PMID: 30486581 DOI: 10.3760/cma.j.issn.0253-2727.2018.11.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Kleczko EK, Kwak JW, Schenk EL, Nemenoff RA. Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer. Front Immunol 2019;10:954. [PMID: 31134065 DOI: 10.3389/fimmu.2019.00954] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
17 Liu SS, Liu YS, Guo XY, Murakami Y, Yang G, Gao XD, Kinoshita T, Fujita M. A knockout cell library of GPI biosynthetic genes for functional studies of GPI-anchored proteins. Commun Biol 2021;4:777. [PMID: 34162996 DOI: 10.1038/s42003-021-02337-1] [Reference Citation Analysis]
18 Vaught AJ, Braunstein EM, Jasem J, Yuan X, Makhlin I, Eloundou S, Baines AC, Merrill SA, Chaturvedi S, Blakemore K, Sperati CJ, Brodsky RA. Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. JCI Insight 2018;3:99128. [PMID: 29563339 DOI: 10.1172/jci.insight.99128] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 11.5] [Reference Citation Analysis]
19 Halder R, Sundaram UKD, Veetil KK, Rath A, Seth T, Tyagi S, Pati HP. Concomitant Existence of Paroxysmal Nocturnal Hemoglobinuria in a Patient with Hb E (HBB: c.79G>A) Trait. Hemoglobin 2020;44:134-6. [PMID: 32354277 DOI: 10.1080/03630269.2020.1759621] [Reference Citation Analysis]
20 Harris CL, Pouw RB, Kavanagh D, Sun R, Ricklin D. Developments in anti-complement therapy; from disease to clinical trial. Mol Immunol 2018;102:89-119. [PMID: 30121124 DOI: 10.1016/j.molimm.2018.06.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 10.3] [Reference Citation Analysis]
21 McKeage K. Ravulizumab: First Global Approval. Drugs 2019;79:347-52. [PMID: 30767127 DOI: 10.1007/s40265-019-01068-2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
22 Bridle TG, Kumarathasan P, Gailer J. Toxic Metal Species and 'Endogenous' Metalloproteins at the Blood-Organ Interface: Analytical and Bioinorganic Aspects. Molecules 2021;26:3408. [PMID: 34199902 DOI: 10.3390/molecules26113408] [Reference Citation Analysis]
23 Semchenkova A, Kashpor S, Verzhbitskaya T, Borisov V, Illarionova O, Fechina L, Maschan A, Novichkova G, Popov A. FLAER-negative CD15+ neutrophils can be used for the simplified screening of suspected PNH cases. Int J Lab Hematol 2020;42:589-93. [PMID: 32449605 DOI: 10.1111/ijlh.13239] [Reference Citation Analysis]
24 Guerrero PA, Murakami Y, Malik A, Seeberger PH, Kinoshita T, Varón Silva D. Rescue of Glycosylphosphatidylinositol-Anchored Protein Biosynthesis Using Synthetic Glycosylphosphatidylinositol Oligosaccharides. ACS Chem Biol 2021;16:2297-306. [PMID: 34618440 DOI: 10.1021/acschembio.1c00465] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
25 Albertini RJ, Kaden DA. Mutagenicity monitoring in humans: Global versus specific origin of mutations. Mutat Res Rev Mutat Res 2020;786:108341. [PMID: 33339577 DOI: 10.1016/j.mrrev.2020.108341] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Patriquin CJ, Kiss T, Caplan S, Chin-Yee I, Grewal K, Grossman J, Larratt L, Marceau D, Nevill T, Sutherland DR, Wells RA, Leber B. How we treat paroxysmal nocturnal hemoglobinuria: A consensus statement of the Canadian PNH Network and review of the national registry. Eur J Haematol 2019;102:36-52. [PMID: 30242915 DOI: 10.1111/ejh.13176] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
27 Conway EM, Pryzdial ELG. Is the COVID-19 thrombotic catastrophe complement-connected? J Thromb Haemost 2020;18:2812-22. [PMID: 32762081 DOI: 10.1111/jth.15050] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
28 Fu R, Li L, Li L, Liu H, Zhang T, Ding S, Wang G, Song J, Wang H, Xing L, Guan J, Shao Z. Analysis of clinical characteristics of 92 patients with paroxysmal nocturnal hemoglobinuria: A single institution experience in China. J Clin Lab Anal 2020;34:e23008. [PMID: 31502726 DOI: 10.1002/jcla.23008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Chai JN, Azad AK, Kuan K, Guo X, Wang Y. A Splice Site Mutation Associated with Congenital CD59 Deficiency. Hematology Reports 2022;14:172-8. [DOI: 10.3390/hematolrep14020025] [Reference Citation Analysis]
30 Revollo JR, Dad A, Pearce MG, Mittelstaedt RA, Robison TW, Dobrovolsky VN. Pig-a mutations in bone marrow erythroblasts of rats treated with 7,12-dimethyl-benz[a]anthracene. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 2019;848:503106. [DOI: 10.1016/j.mrgentox.2019.503106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
31 Langemeijer S, Schaap C, Preijers F, Jansen JH, Blijlevens N, Inoue N, Muus P, Kinoshita T, Murakami Y. Paroxysmal nocturnal hemoglobinuria caused by CN-LOH of constitutional PIGB mutation and 70-kbp microdeletion on 15q. Blood Adv 2020;4:5755-61. [PMID: 33216889 DOI: 10.1182/bloodadvances.2020002210] [Reference Citation Analysis]
32 Shin B, Won H, Adams DJ, Lee SK. CD55 Regulates Bone Mass in Mice by Modulating RANKL-Mediated Rac Signaling and Osteoclast Function. J Bone Miner Res 2020;35:130-42. [PMID: 31487060 DOI: 10.1002/jbmr.3861] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
33 Park SJ, Bejar R. Clonal Hematopoiesis in Aging. Curr Stem Cell Rep 2018;4:209-19. [PMID: 30854305 DOI: 10.1007/s40778-018-0133-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
34 Zarantonello A, Pedersen H, Laursen NS, Andersen GR. Nanobodies Provide Insight into the Molecular Mechanisms of the Complement Cascade and Offer New Therapeutic Strategies. Biomolecules 2021;11:298. [PMID: 33671302 DOI: 10.3390/biom11020298] [Reference Citation Analysis]
35 Chatzidavid S, Giannakopoulou N, Diamantopoulos PT, Gavriilaki E, Katsiampoura P, Lakiotaki E, Sakellariou S, Viniou NA, Dryllis G. JAK2V617F positive polycythemia vera with paroxysmal nocturnal hemoglobinuria and visceral thromboses: a case report and review of the literature. Thromb J 2021;19:16. [PMID: 33691713 DOI: 10.1186/s12959-021-00269-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Kokoris SI, Gavriilaki E, Miari A, Travlou Α, Kyriakou E, Anagnostopoulos A, Grouzi E. Renal involvement in paroxysmal nocturnal hemoglobinuria: an update on clinical features, pathophysiology and treatment. Hematology 2018;23:558-66. [PMID: 29486674 DOI: 10.1080/10245332.2018.1444563] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
37 Vyrides N, Douka V, Gavriilaki E, Papaioannou G, Athanasiadou A, Neofytou S, Vyrides Y, Lalayanni C, Anagnostopoulos A, Kokoris SI. Paroxysmal nocturnal hemoglobinuria and myelodysplastic syndrome: Disappearance of cytogenetic abnormalities. Cancer Genet 2021;250-251:1-5. [PMID: 33188967 DOI: 10.1016/j.cancergen.2020.11.001] [Reference Citation Analysis]
38 Schröder-Braunstein J, Kirschfink M. Complement deficiencies and dysregulation: Pathophysiological consequences, modern analysis, and clinical management. Mol Immunol 2019;114:299-311. [PMID: 31421540 DOI: 10.1016/j.molimm.2019.08.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
39 Lin K, Zhang L, Kong M, Yang M, Chen Y, Poptic E, Hoffner M, Xu J, Tam C, Lin F. Development of an anti-human complement C6 monoclonal antibody that inhibits the assembly of membrane attack complexes. Blood Adv 2020;4:2049-57. [PMID: 32396613 DOI: 10.1182/bloodadvances.2020001690] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
40 Oncul S, Afshar-Kharghan V. The interaction between the complement system and hemostatic factors. Curr Opin Hematol 2020;27:341-52. [PMID: 32701617 DOI: 10.1097/MOH.0000000000000605] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
41 Rehan ST, Hashmi MR, Asghar MS, Tahir MJ, Yousaf Z. Pegcetacoplan ‐ a novel C3 inhibitor for paroxysmal nocturnal hemoglobinuria. Health Science Reports 2022;5. [DOI: 10.1002/hsr2.512] [Reference Citation Analysis]
42 Chen JY, Galwankar NS, Emch HN, Menon SS, Cortes C, Thurman JM, Merrill SA, Brodsky RA, Ferreira VP. Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation. Front Immunol 2020;11:1460. [PMID: 32793201 DOI: 10.3389/fimmu.2020.01460] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
43 Gembillo G, Siligato R, Cernaro V, Santoro D. Complement Inhibition Therapy and Dialytic Strategies in Paroxysmal Nocturnal Hemoglobinuria: The Nephrologist's Opinion. J Clin Med 2020;9:E1261. [PMID: 32357555 DOI: 10.3390/jcm9051261] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Sica M, Pellecchia A, De Angioletti M, Caocci G, Nannelli C, La Nasa G, Luzzatto L, Notaro R. Complement-mediated oxidative damage of red cells impairs response to eculizumab in a G6PD-deficient patient with PNH. Blood 2020;136:3082-5. [PMID: 32845970 DOI: 10.1182/blood.2020007780] [Reference Citation Analysis]
45 Sarpong-Kumankomah S, Gailer J. Identification of a haptoglobin-hemoglobin complex in human blood plasma. J Inorg Biochem. 2019;201:110802. [PMID: 31514091 DOI: 10.1016/j.jinorgbio.2019.110802] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
46 Marchesi RF, Velloso EDRP, Garanito MP, Leal AM, Siqueira SAC, Azevedo Neto RS, Rocha V, Zerbini MCN. Clinical impact of dysplastic changes in acquired aplastic anemia: A systematic study of bone marrow biopsies in children and adults. Ann Diagn Pathol 2020;45:151459. [PMID: 32000075 DOI: 10.1016/j.anndiagpath.2019.151459] [Reference Citation Analysis]
47 Bravo-pérez C, Carrillo-tornel S, García-torralba E, Jerez A. Persistent Large Granular Lymphocyte Clonal Expansions: “The Root of Many Evils”—And of Some Goodness. Cancers 2022;14:1340. [DOI: 10.3390/cancers14051340] [Reference Citation Analysis]
48 Gullipalli D, Zhang F, Sato S, Ueda Y, Kimura Y, Golla M, Miwa T, Wang J, Song WC. Antibody Inhibition of Properdin Prevents Complement-Mediated Intravascular and Extravascular Hemolysis. J Immunol 2018;201:1021-9. [PMID: 29898960 DOI: 10.4049/jimmunol.1800384] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
49 Rawish E, Sauter M, Sauter R, Nording H, Langer HF. Complement, inflammation and thrombosis. Br J Pharmacol 2021;178:2892-904. [PMID: 33817781 DOI: 10.1111/bph.15476] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Afzali B, Noris M, Lambrecht BN, Kemper C. The state of complement in COVID-19. Nat Rev Immunol 2021. [PMID: 34912108 DOI: 10.1038/s41577-021-00665-1] [Reference Citation Analysis]
51 Li Y, Clow F, Fraser JD, Lin F. Therapeutic potential of staphylococcal superantigen-like protein 7 for complement-mediated hemolysis. J Mol Med (Berl) 2018;96:965-74. [PMID: 30066197 DOI: 10.1007/s00109-018-1678-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
52 Wu Y, Wu Y, Ji Y, Liu Y, Wu D, Liang J, Guo G, Chen B. Case Report: Oral Cimetidine Administration Causes Drug-Induced Immune Hemolytic Anemia by Eliciting the Production of Cimetidine-Dependent Antibodies and Drug-Independent Non-specific Antibodies. Front Med (Lausanne) 2021;8:723167. [PMID: 34646843 DOI: 10.3389/fmed.2021.723167] [Reference Citation Analysis]
53 Park J, Kim M, Kim Y, Han K, Chung NG, Cho B, Lee SE, Lee JW. Clonal Cell Proliferation in Paroxysmal Nocturnal Hemoglobinuria: Evaluation of PIGA Mutations and T-cell Receptor Clonality. Ann Lab Med 2019;39:438-46. [PMID: 31037862 DOI: 10.3343/alm.2019.39.5.438] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
54 Cooper JP, Farah RJ, Stevenson PA, Gooley TA, Storb R, Scott BL. Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab. Biol Blood Marrow Transplant 2019;25:1331-9. [PMID: 30711779 DOI: 10.1016/j.bbmt.2019.01.033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
55 Brodszki N, Frazer-Abel A, Grumach AS, Kirschfink M, Litzman J, Perez E, Seppänen MRJ, Sullivan KE, Jolles S. European Society for Immunodeficiencies (ESID) and European Reference Network on Rare Primary Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN RITA) Complement Guideline: Deficiencies, Diagnosis, and Management. J Clin Immunol 2020;40:576-91. [PMID: 32064578 DOI: 10.1007/s10875-020-00754-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
56 Oved JH, Stanley N, Babushok DV, Huang Y, Duke JL, Monos DS, Teachey DT, Olson TS. Development of hemolytic paroxysmal nocturnal hemoglobinuria without graft loss following hematopoietic stem cell transplantation for acquired aplastic anemia. Pediatr Transplant 2019;23:e13393. [PMID: 30900367 DOI: 10.1111/petr.13393] [Reference Citation Analysis]
57 Rosa J, Arruda A, Rodrigues AL, Soares MR. Paroxysmal Nocturnal Hemoglobinuria: Case Report of a Rare Cause of Thrombosis in the Pediatric Age. J Pediatr Hematol Oncol 2021;43:e240-2. [PMID: 31842179 DOI: 10.1097/MPH.0000000000001701] [Reference Citation Analysis]
58 Dzik S. Complement and Coagulation: Cross Talk Through Time. Transfus Med Rev 2019;33:199-206. [PMID: 31672340 DOI: 10.1016/j.tmrv.2019.08.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
59 Wang Y, Hirata T, Maeda Y, Murakami Y, Fujita M, Kinoshita T. Free, unlinked glycosylphosphatidylinositols on mammalian cell surfaces revisited. J Biol Chem 2019;294:5038-49. [PMID: 30728244 DOI: 10.1074/jbc.RA119.007472] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
60 Arcavi M, Ceballo F, Caracciolo MB, Lazarowski A. Paroxysmal nocturnal hemoglobinuria: Test to monitor the action of eculizumab treatment. Int J Lab Hematol 2020;42:335-40. [PMID: 32202389 DOI: 10.1111/ijlh.13186] [Reference Citation Analysis]
61 Li J, Lin Y, Chen L, Qin L, Tan H, Zou J, Zhang D, Nie Y, Wang G, Zhang H, Liu E, Chen X, Ru K. Identification of acquired PIGA mutations and additional variants by next-generation sequencing in paroxysmal nocturnal hemoglobinuria. Int J Lab Hematol 2020;42:473-81. [PMID: 32359022 DOI: 10.1111/ijlh.13228] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
62 Bemis JC, Heflich RH. In vitro mammalian cell mutation assays based on the Pig-a gene: A report of the 7th International Workshop on Genotoxicity Testing (IWGT) Workgroup. Mutat Res Genet Toxicol Environ Mutagen 2019;847:403028. [PMID: 31699348 DOI: 10.1016/j.mrgentox.2019.03.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
63 Nishimura JI, Usuki K, Ramos J, Ichikawa S, Buri M, Kiialainen A, Sostelly A, Peffault de Latour R, Paz-Priel I, Röth A. Crovalimab for treatment of patients with paroxysmal nocturnal haemoglobinuria and complement C5 polymorphism: Subanalysis of the phase 1/2 COMPOSER study. Br J Haematol 2022. [PMID: 35608260 DOI: 10.1111/bjh.18274] [Reference Citation Analysis]
64 Yoo JJ, Chonat S. Evaluating ravulizumab for the treatment of children and adolescents with paroxysmal nocturnal hemoglobinuria. Expert Rev Hematol 2022. [PMID: 35502699 DOI: 10.1080/17474086.2022.2073215] [Reference Citation Analysis]
65 Chen F, Hu S, Ruan J, Chen M, Han B. Mutational landscape and its clinical significance in paroxysmal nocturnal hemoglobinuria. Blood Cancer J 2021;11:58. [PMID: 33727526 DOI: 10.1038/s41408-021-00451-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Plášek J, Gumulec J, Máca J, Škarda J, Procházka V, Grézl T, Václavík J. COVID-19 Associated Coagulopathy: Mechanisms and Host-Directed Treatment. Am J Med Sci 2021:S0002-9629(21)00403-1. [PMID: 34752741 DOI: 10.1016/j.amjms.2021.10.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Pouw RB, Ricklin D. Tipping the balance: intricate roles of the complement system in disease and therapy. Semin Immunopathol 2021;43:757-71. [PMID: 34698894 DOI: 10.1007/s00281-021-00892-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Chonat S, Mener A, Verkerke H, Stowell SR. Role of complement in alloimmunization and hyperhemolysis. Curr Opin Hematol 2020;27:406-14. [PMID: 32889827 DOI: 10.1097/MOH.0000000000000610] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
69 Manning JE, Anderson RM, Hill A, Zeidan D, Ciantar E. Pregnancy outcomes in women receiving eculizumab for the management of paroxysmal nocturnal haemoglobinuria. Obstet Med. [DOI: 10.1177/1753495x211019899] [Reference Citation Analysis]
70 Ishiyama K, Nakao S, Usuki K, Yonemura Y, Ikezoe T, Uchiyama M, Mori Y, Fukuda T, Okada M, Fujiwara SI, Noji H, Rottinghaus S, Aguzzi R, Yokosawa J, Nishimura JI, Kanakura Y, Okamoto S. Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients. Int J Hematol 2020;112:466-76. [PMID: 32869125 DOI: 10.1007/s12185-020-02934-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
71 Johansson P, Klein-Hitpass L, Röth A, Möllmann M, Reinhardt HC, Dührsen U, Dürig J. Mutations in PIGA cause a CD52-/GPI-anchor-deficient phenotype complicating alemtuzumab treatment in T-cell prolymphocytic leukemia. Eur J Haematol 2020;105:786-96. [PMID: 32875608 DOI: 10.1111/ejh.13511] [Reference Citation Analysis]
72 Kinoshita T. Biosynthesis and biology of mammalian GPI-anchored proteins. Open Biol 2020;10:190290. [PMID: 32156170 DOI: 10.1098/rsob.190290] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 21.0] [Reference Citation Analysis]
73 Ilhan O, Ozdemir ZN, Ozet G, Falay M, Yenerel M, Tuglular T, Turgut M, Guvenc B, Unal A, Ayyıldız O, Andic N, Hacıhanefioglu A, Sahin F, Sencan M, Ali R, Ozsan GH, Yildirim R, Tiftik EN, Tombak A, Salim O, Kaya E, Akay OM, Okan V, Pehlivan M, Saydam G. Study for the diagnostic screening of paroxsymal nocturnal hemoglobinuria in Turkey: Prospective multicentric evaluation of suspected patients. Transfus Apher Sci 2019;58:659-62. [PMID: 31542336 DOI: 10.1016/j.transci.2019.08.021] [Reference Citation Analysis]
74 Yılmaz F, Soyer N, Cengiz Seval G, Civriz Bozdağ S, Topcuoğlu P, Ünal A, Kaynar L, Özgür G, Sucak G, Göker H, Velet M, Özdoğu H, Yılmaz M, Kaya E, Salim O, Deveci B, Karadoğan İ, Saydam G, Şahin F, Vural F. Hematopoietic Stem Cell Transplantation for Patients with Paroxysmal Nocturnal Hemoglobinuria with or without Aplastic Anemia: A Multicenter Turkish Experience. Turk J Haematol 2021;38:195-203. [PMID: 34057336 DOI: 10.4274/tjh.galenos.2021.2021.0105] [Reference Citation Analysis]
75 Brodsky RA, Lee JW, Nishimura JI, Szer J. Lactate dehydrogenase versus haemoglobin: which one is the better marker in paroxysmal nocturnal haemoglobinuria? Br J Haematol 2021. [PMID: 34923628 DOI: 10.1111/bjh.17860] [Reference Citation Analysis]
76 Albertini RJ, Nicklas JA, Vacek PM, Carter EW, McDiarmid M. Longitudinal study of t-cell somatic mutations conferring glycosylphosphatidylinositol-anchor deficiency in gulf war I veterans exposed to depleted uranium. Environ Mol Mutagen 2019;60:494-504. [PMID: 30848527 DOI: 10.1002/em.22281] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
77 Vaught AJ, Braunstein E, Chaturvedi S, Blakemore K, Brodsky RA. A review of the alternative pathway of complement and its relation to HELLP syndrome: is it time to consider HELLP syndrome a disease of the alternative pathway. J Matern Fetal Neonatal Med 2020;:1-9. [PMID: 32338085 DOI: 10.1080/14767058.2020.1755650] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
78 Cheng WY, Sarda SP, Mody-Patel N, Krishnan S, Yenikomshian M, Mahendran M, Lejeune D, Yu LH, Duh MS. Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population. Adv Ther 2021;38:4461-79. [PMID: 34275086 DOI: 10.1007/s12325-021-01825-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
79 Jalink M, de Boer ECW, Evers D, Havinga MQ, Vos JMI, Zeerleder S, de Haas M, Jongerius I. Halting targeted and collateral damage to red blood cells by the complement system. Semin Immunopathol 2021. [PMID: 34191092 DOI: 10.1007/s00281-021-00859-8] [Reference Citation Analysis]
80 Höchsmann B, Murakami Y, Osato M, Knaus A, Kawamoto M, Inoue N, Hirata T, Murata S, Anliker M, Eggermann T, Jäger M, Floettmann R, Höllein A, Murase S, Ueda Y, Nishimura JI, Kanakura Y, Kohara N, Schrezenmeier H, Krawitz PM, Kinoshita T. Complement and inflammasome overactivation mediates paroxysmal nocturnal hemoglobinuria with autoinflammation. J Clin Invest 2019;129:5123-36. [PMID: 31430258 DOI: 10.1172/JCI123501] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
81 Kwoun WJ, Lee HT, Ahn JY. Frequencies of glycosylphosphatidylinositol (GPI)-deficient cells using high-sensitivity flow cytometry as per the 2018 ICCS/ESCCA consensus guideline in patients with hematologic malignancy, aplastic anemia, or cytopenia. Expert Rev Hematol 2022. [PMID: 35119350 DOI: 10.1080/17474086.2022.2038561] [Reference Citation Analysis]
82 Halder R, Mishra P, Aggarwal M, Mannivanan P, Dhawan R, Seth T, Tyagi S, Mahapatra M, Pati HP, Saxena R. Outcomes of paroxysmal nocturnal hemoglobinuria in the pediatric age group in a resource-constrained setting. Pediatr Blood Cancer 2020;67:e27712. [PMID: 30912620 DOI: 10.1002/pbc.27712] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
83 Wang H, Chen Y, Liu H, Liu Z, Fu R. Long Non-Coding RNA MALAT1 Contributed to the Proliferation of PNH Clone in Paroxysmal Nocturnal Hemoglobinuria Patients. Turk J Haematol 2021;38:236-8. [PMID: 33726486 DOI: 10.4274/tjh.galenos.2021.2021.0065] [Reference Citation Analysis]
84 Cell Analysis Committee, Chinese} Society of Biotechnology., Clinical Flow Cytometry Group, Blood Immune Committee, Chinese Society of Immunology., Red Blood Cell Disease (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association. [Chinese expert consensus on paroxysmal nocturnal hemoglobinuria detection via flow cytometry (2021)]. Zhonghua Xue Ye Xue Za Zhi 2021;42:281-7. [PMID: 33979971 DOI: 10.3760/cma.j.issn.0253-2727.2021.04.003] [Reference Citation Analysis]
85 Dobó J, Kocsis A, Gál P. Be on Target: Strategies of Targeting Alternative and Lectin Pathway Components in Complement-Mediated Diseases. Front Immunol 2018;9:1851. [PMID: 30135690 DOI: 10.3389/fimmu.2018.01851] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
86 Schär DT, Daskalakis M, Mansouri B, Rovo A, Zeerleder S. Thromboembolic complications in autoimmune hemolytic anemia: Retrospective study. Eur J Haematol 2022;108:45-51. [PMID: 34551149 DOI: 10.1111/ejh.13710] [Reference Citation Analysis]
87 Brodsky RA. A complementary new drug for PNH. Blood 2020;135:884-5. [PMID: 32191798 DOI: 10.1182/blood.2020004959] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Sun L, Babushok DV. Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria. Blood 2020;136:36-49. [PMID: 32430502 DOI: 10.1182/blood.2019000940] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
89 Fonseca AC, Silva DP, Infante J, Ferro JM. Cerebrovascular Complications of Anemia. Curr Neurol Neurosci Rep 2021;21:51. [PMID: 34480226 DOI: 10.1007/s11910-021-01141-y] [Reference Citation Analysis]
90 Nakamura Y, Takenaka K, Yamazaki H, Onishi Y, Ozawa Y, Ikegame K, Matsuoka KI, Toubai T, Ueda Y, Kanda Y, Ichinohe T, Atsuta Y, Mori T. Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with paroxysmal nocturnal hemoglobinuria. Int J Hematol 2021;113:122-7. [PMID: 32889696 DOI: 10.1007/s12185-020-02982-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
91 Cruz DS, da Silva Santos M, Santos B. Cost-Utility Analysis of Eculizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria from the Perspective of the Brazilian Public Health System. Value Health Reg Issues 2021;26:113-25. [PMID: 34332185 DOI: 10.1016/j.vhri.2021.03.003] [Reference Citation Analysis]
92 Xu B. Novel targeted C3 inhibitor pegcetacoplan for paroxysmal nocturnal hemoglobinuria. Clin Exp Med 2022. [PMID: 35441351 DOI: 10.1007/s10238-022-00830-3] [Reference Citation Analysis]
93 Pasca S, Gondek LP. Clonal hematopoiesis and bone marrow failure syndromes. Best Pract Res Clin Haematol 2021;34:101273. [PMID: 34404525 DOI: 10.1016/j.beha.2021.101273] [Reference Citation Analysis]
94 Miller K, Sarpong-Kumankomah S, Egorov A, Gailer J. Sample preparation of blood plasma enables baseline separation of iron metalloproteins by SEC-GFAAS. J Chromatogr B Analyt Technol Biomed Life Sci 2020;1147:122147. [PMID: 32416595 DOI: 10.1016/j.jchromb.2020.122147] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
95 Chen Y, Rong F. Advances in the creation of animal models of paroxysmal nocturnal hemoglobinuria. Hematology 2021;26:491-6. [PMID: 34238137 DOI: 10.1080/16078454.2021.1945244] [Reference Citation Analysis]
96 Pedersen DV, Gadeberg TAF, Thomas C, Wang Y, Joram N, Jensen RK, Mazarakis SMM, Revel M, El Sissy C, Petersen SV, Lindorff-Larsen K, Thiel S, Laursen NS, Fremeaux-Bacchi V, Andersen GR. Structural Basis for Properdin Oligomerization and Convertase Stimulation in the Human Complement System. Front Immunol 2019;10:2007. [PMID: 31507604 DOI: 10.3389/fimmu.2019.02007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
97 Leth JM, Ploug M. Targeting the Urokinase-Type Plasminogen Activator Receptor (uPAR) in Human Diseases With a View to Non-invasive Imaging and Therapeutic Intervention. Front Cell Dev Biol 2021;9:732015. [PMID: 34490277 DOI: 10.3389/fcell.2021.732015] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Kulasekararaj AG, Brodsky RA, Nishimura JI, Patriquin CJ, Schrezenmeier H. The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria. Ther Adv Hematol 2022;13:20406207221091046. [PMID: 35663504 DOI: 10.1177/20406207221091046] [Reference Citation Analysis]
99 Schaap CCM, Grotens A, de Haan AFJ, Blijlevens NMA, Langemeijer SMC. Infections during eculizumab therapy in a Dutch population of patients with paroxysmal nocturnal haemoglobinuria. Clin Microbiol Infect 2021:S1198-743X(21)00361-X. [PMID: 34197930 DOI: 10.1016/j.cmi.2021.06.030] [Reference Citation Analysis]
100 Frazer-Abel A. The effect on the immunology laboratory of the expansion in complement therapeutics. J Immunol Methods 2018;461:30-6. [PMID: 30092178 DOI: 10.1016/j.jim.2018.08.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
101 Lee-Sundlov MM, Stowell SR, Hoffmeister KM. Multifaceted role of glycosylation in transfusion medicine, platelets, and red blood cells. J Thromb Haemost 2020;18:1535-47. [PMID: 32350996 DOI: 10.1111/jth.14874] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
102 Cao H, Zhang G, Ciociola K, Amaravadi L, Qiu Y, Wu J. An LC–MS/MS approach to assess total and free protein target in the serum of cynomolgus monkey. Bioanalysis 2019;11:393-406. [DOI: 10.4155/bio-2018-0294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
103 Holste K, Xia F, Garton HJL, Wan S, Hua Y, Keep RF, Xi G. The role of complement in brain injury following intracerebral hemorrhage: A review. Exp Neurol 2021;340:113654. [PMID: 33617886 DOI: 10.1016/j.expneurol.2021.113654] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Alashkar F, Saner FH, Vance C, Schmücker U, Herich-Terhürne D, Dührsen U, Köninger A, Röth A. Pregnancy in Classical Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia-Paroxysmal Nocturnal Hemoglobinuria: A High-Risk Constellation. Front Med (Lausanne) 2020;7:543372. [PMID: 33102497 DOI: 10.3389/fmed.2020.543372] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
105 Peron A, Iascone M, Salvatici E, Cavirani B, Marchetti D, Corno S, Vignoli A. PIGW-related glycosylphosphatidylinositol deficiency: Description of a new patient and review of the literature. Am J Med Genet A 2020;182:1477-82. [PMID: 32198969 DOI: 10.1002/ajmg.a.61555] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
106 Fletcher-Sandersjöö A, Maegele M, Bellander BM. Does Complement-Mediated Hemostatic Disturbance Occur in Traumatic Brain Injury? A Literature Review and Observational Study Protocol. Int J Mol Sci 2020;21:E1596. [PMID: 32111078 DOI: 10.3390/ijms21051596] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
107 Beato Merino MJ, Diago A, Fernández-Flores Á, Fraga J, García Herrera A, Garrido M, Idoate Gastearena MÁ, Llamas-Velasco M, Monteagudo C, Onrubia J, Pérez-González YC, Pérez Muñoz N, Ríos-Martín JJ, Ríos-Viñuela E, Rodríguez Peralto JL, Rozas Muñoz E, Sanmartín O, Santonja C, Santos-Briz Á, Saus C, Suárez Peñaranda JM, Velasco Benito V. Clinical and Histopathologic Characteristics of the Main Causes of Vascular Occlusion - Part I: Thrombi. Actas Dermosifiliogr (Engl Ed) 2021;112:1-13. [PMID: 33045208 DOI: 10.1016/j.ad.2020.09.006] [Reference Citation Analysis]
108 Luzzatto L, Makani J. Treating Rare Diseases in Africa: The Drugs Exist but the Need Is Unmet. Front Pharmacol 2021;12:770640. [PMID: 35082665 DOI: 10.3389/fphar.2021.770640] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood 2021;137:1304-9. [PMID: 33512400 DOI: 10.1182/blood.2019003812] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
110 DeZern AE, Churpek JE. Approach to the diagnosis of aplastic anemia. Blood Adv 2021;5:2660-71. [PMID: 34156438 DOI: 10.1182/bloodadvances.2021004345] [Reference Citation Analysis]
111 Jaime-Pérez JC, González-Treviño M, Gómez-Almaguer D. Pregnancy-associated aplastic anemia: a case-based review. Expert Rev Hematol 2021;14:175-84. [PMID: 33430674 DOI: 10.1080/17474086.2021.1875816] [Reference Citation Analysis]
112 Tomazos I, Sierra JR, Johnston KM, Cheung A, Brodsky RA, Weitz IC. Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab. Hematology 2020;25:327-34. [PMID: 32856539 DOI: 10.1080/16078454.2020.1807226] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
113 Jeong D, Park HS, Kim SM, Im K, Yun J, Lee YE, Ryu S, Ahn YO, Yoon SS, Lee DS. Ultradeep Sequencing Analysis of Paroxysmal Nocturnal Hemoglobinuria Clones Detected by Flow Cytometry: PIG Mutation in Small PNH Clones. Am J Clin Pathol 2021;156:72-85. [PMID: 33347536 DOI: 10.1093/ajcp/aqaa211] [Reference Citation Analysis]
114 Yang W, Zhao X, Peng G, Zhang L, Jing L, Zhou K, Li Y, Ye L, Li Y, Li J, Fan H, Yang Y, Zhang F. Time and residual hematopoiesis are crucial for PNH clones escape in hepatitis-associated aplastic anemia. Ann Hematol 2021. [PMID: 34269836 DOI: 10.1007/s00277-021-04553-5] [Reference Citation Analysis]
115 Brodsky RA. Paroxysmal nocturnal hemoglobinuria without GPI-anchor deficiency. J Clin Invest 2019;129:5074-6. [PMID: 31638602 DOI: 10.1172/JCI131647] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
116 Barcellini W, Scola E, Lanfranconi S, Grottaroli M, Binda F, Fattizzo B, Zaninoni A, Valcamonica G, Cinnante CM, Boschetti C, Buoli M, Altamura CA, Bresolin N, Triulzi F, Zanella A, Cortelezzi A. Paroxysmal Nocturnal Hemoglobinuria (Pnh): Brain Mri Ischemic Lesions In Neurologically Asymtomatic Patients. Sci Rep 2018;8:476. [PMID: 29323198 DOI: 10.1038/s41598-017-18936-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
117 Patriquin CJ, Kuo KHM. Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics. Transfus Med Rev 2019;33:256-65. [PMID: 31703946 DOI: 10.1016/j.tmrv.2019.09.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
118 Mishra P, Tripathi P, Halder R, Saxena R, Tyagi S, Mahapatra M, Pati HP. Clinico-Hematological Profile of Paroxysmal Nocturnal Hemoglobinuria in Indian Patients: FLAER Flow Cytometry Based Experience from an Indian Tertiary Care Centre. Indian J Hematol Blood Transfus 2021;37:220-5. [PMID: 33867727 DOI: 10.1007/s12288-020-01302-y] [Reference Citation Analysis]
119 Zhang L, Chen JY, Kerr C, Cobb BA, Maciejewski JP, Lin F. Reduced red blood cell surface level of Factor H as a mechanism underlying paroxysmal nocturnal hemoglobinuria. Leukemia 2021;35:1176-87. [PMID: 32814838 DOI: 10.1038/s41375-020-1008-5] [Reference Citation Analysis]
120 Chan RC, Leung RH, Posadas A, Lorey TS, Shaw AJ. High sensitivity 8-color flow cytometry assay for paroxysmal nocturnal hemoglobinuria granulocyte and monocyte detections. Biomed Rep 2018;8:224-34. [PMID: 29599976 DOI: 10.3892/br.2018.1047] [Reference Citation Analysis]
121 Stefanovic V. The Extended Use of Eculizumab in Pregnancy and Complement Activation⁻Associated Diseases Affecting Maternal, Fetal and Neonatal Kidneys-The Future Is Now? J Clin Med 2019;8:E407. [PMID: 30909646 DOI: 10.3390/jcm8030407] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
122 Li L, Liu H, Wang H, Liu Z, Chen Y, Liu C, Zhao X, Li L, Wang H, Shao Z, Fu R. Clinical observation of low-dose combination chemotherapy in refractory/recurrent paroxysmal nocturnal hemoglobinuria patients: A single-center retrospective analysis. J Clin Lab Anal 2022;:e24239. [PMID: 35028973 DOI: 10.1002/jcla.24239] [Reference Citation Analysis]
123 Gutwein O, Englander Y, Herzog-Tzarfati K, Filipovich-Rimon T, Apel A, Marcus R, Rahimi-Levene N, Koren-Michowitz M. Prevalence of Paroxysmal Nocturnal Hemoglobinuria Clones in Myeloproliferative Neoplasm Patients: A Cross-Sectional Study. Clin Lymphoma Myeloma Leuk 2019;19:812-4. [PMID: 31601527 DOI: 10.1016/j.clml.2019.07.441] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
124 Wong EKS, Kavanagh D. Diseases of complement dysregulation-an overview. Semin Immunopathol 2018;40:49-64. [PMID: 29327071 DOI: 10.1007/s00281-017-0663-8] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
125 Patel RA, Hall DA, Eichenseer S, Bailey M. Movement Disorders and Hematologic Diseases. Mov Disord Clin Pract 2021;8:193-207. [PMID: 33553488 DOI: 10.1002/mdc3.13129] [Reference Citation Analysis]
126 Fukuzawa T, Nezu J. SKY59, A Novel Recycling Antibody for Complement-mediated Diseases. Curr Med Chem 2020;27:4157-64. [PMID: 31622197 DOI: 10.2174/0929867326666191016115853] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
127 Santiesteban-Lores LE, Amamura TA, da Silva TF, Midon LM, Carneiro MC, Isaac L, Bavia L. A double edged-sword - The Complement System during SARS-CoV-2 infection. Life Sci 2021;272:119245. [PMID: 33609539 DOI: 10.1016/j.lfs.2021.119245] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
128 Henrique Silva F, Yotsumoto Fertrin K, Costa Alexandre E, Beraldi Calmasini F, Fernanda Franco-Penteado C, Ferreira Costa F. Impairment of Nitric Oxide Pathway by Intravascular Hemolysis Plays a Major Role in Mice Esophageal Hypercontractility: Reversion by Soluble Guanylyl Cyclase Stimulator. J Pharmacol Exp Ther 2018;367:194-202. [PMID: 30108160 DOI: 10.1124/jpet.118.249581] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
129 Ferro JM, Infante J. Cerebrovascular manifestations in hematological diseases: an update.J Neurol. 2021;268:3480-3492. [PMID: 33586004 DOI: 10.1007/s00415-021-10441-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
130 Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, Pessoa V, Gualandro S, Füreder W, Ptushkin V, Rottinghaus ST, Volles L, Shafner L, Aguzzi R, Pradhan R, Schrezenmeier H, Hill A. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood 2019;133:530-9. [PMID: 30510080 DOI: 10.1182/blood-2018-09-876136] [Cited by in Crossref: 88] [Cited by in F6Publishing: 78] [Article Influence: 22.0] [Reference Citation Analysis]
131 Merrill SA, Brodsky RA. Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria. Hematology Am Soc Hematol Educ Program 2018;2018:371-6. [PMID: 30504334 DOI: 10.1182/asheducation-2018.1.371] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
132 Fletcher-Sandersjöö A, Bellander BM. Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review. Thromb Res 2020;194:36-41. [PMID: 32569879 DOI: 10.1016/j.thromres.2020.06.027] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 24.0] [Reference Citation Analysis]
133 Balla J, Zarjou A. Heme Burden and Ensuing Mechanisms That Protect the Kidney: Insights from Bench and Bedside. Int J Mol Sci 2021;22:8174. [PMID: 34360940 DOI: 10.3390/ijms22158174] [Reference Citation Analysis]
134 Huang Y, Liu X, Chen F, Zhou W, Li H, Long Z, Yang C, Chen M, Han B. Prediction of thrombosis risk in patients with paroxysmal nocturnal hemoglobinuria. Ann Hematol 2019;98:2283-91. [PMID: 31396670 DOI: 10.1007/s00277-019-03770-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
135 Trouw LA, Pickering MC, Blom AM. The complement system as a potential therapeutic target in rheumatic disease. Nat Rev Rheumatol 2017;13:538-47. [DOI: 10.1038/nrrheum.2017.125] [Cited by in Crossref: 95] [Cited by in F6Publishing: 84] [Article Influence: 19.0] [Reference Citation Analysis]
136 Hoy SM. Pegcetacoplan: First Approval. Drugs 2021;81:1423-30. [PMID: 34342834 DOI: 10.1007/s40265-021-01560-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
137 Freitas Leal JK, Preijers F, Brock R, Adjobo-Hermans M, Bosman G. Red Blood Cell Homeostasis and Altered Vesicle Formation in Patients With Paroxysmal Nocturnal Hemoglobinuria. Front Physiol 2019;10:578. [PMID: 31156458 DOI: 10.3389/fphys.2019.00578] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
138 Simmons KT, Mazzilli JL, Mueller-Ortiz SL, Domozhirov AY, Garcia CA, Zsigmond EM, Wetsel RA. Complement Receptor 1 (CR1/CD35)-expressing retinal pigment epithelial cells as a potential therapy for age-related macular degeneration. Mol Immunol 2020;118:91-8. [PMID: 31862673 DOI: 10.1016/j.molimm.2019.11.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
139 Lukacs M, Roberts T, Chatuverdi P, Stottmann RW. Glycosylphosphatidylinositol biosynthesis and remodeling are required for neural tube closure, heart development, and cranial neural crest cell survival. Elife 2019;8:e45248. [PMID: 31232685 DOI: 10.7554/eLife.45248] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
140 Jensen RK, Pihl R, Gadeberg TAF, Jensen JK, Andersen KR, Thiel S, Laursen NS, Andersen GR. A potent complement factor C3-specific nanobody inhibiting multiple functions in the alternative pathway of human and murine complement. J Biol Chem 2018;293:6269-81. [PMID: 29497000 DOI: 10.1074/jbc.RA117.001179] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
141 Pokhrel B, Gautam S, Khanal S, Pokhrel NB, Shrestha A. A Rare and Misdiagnosed Entity Paroxysmal Nocturnal Hemoglobinuria: A Case Report. Cureus 2021;13:e14902. [PMID: 34109088 DOI: 10.7759/cureus.14902] [Reference Citation Analysis]
142 Annarapu GK, Nolfi-Donegan D, Reynolds M, Wang Y, Kohut L, Zuckerbraun B, Shiva S. Heme stimulates platelet mitochondrial oxidant production to induce targeted granule secretion. Redox Biol 2021;48:102205. [PMID: 34891098 DOI: 10.1016/j.redox.2021.102205] [Reference Citation Analysis]
143 Zhou P, He N, Zhang JW, Lin ZJ, Wang J, Yan LM, Meng H, Tang B, Li BM, Liu XR, Shi YW, Zhai QX, Yi YH, Liao WP. Novel mutations and phenotypes of epilepsy-associated genes in epileptic encephalopathies. Genes Brain Behav 2018;17:e12456. [PMID: 29314583 DOI: 10.1111/gbb.12456] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
144 Gris J, Chéa M, Guillotin F, Fortier M, Bourguignon C, Mercier É, Bouvier S. Thrombosis and paroxysmal nocturnal haemoglobinuria. Thrombosis Update 2021;5:100074. [DOI: 10.1016/j.tru.2021.100074] [Reference Citation Analysis]
145 Kulasekararaj AG, Hill A, Rottinghaus ST, Langemeijer S, Wells R, Gonzalez-Fernandez FA, Gaya A, Lee JW, Gutierrez EO, Piatek CI, Szer J, Risitano A, Nakao S, Bachman E, Shafner L, Damokosh AI, Ortiz S, Röth A, Peffault de Latour R. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood 2019;133:540-9. [PMID: 30510079 DOI: 10.1182/blood-2018-09-876805] [Cited by in Crossref: 102] [Cited by in F6Publishing: 80] [Article Influence: 25.5] [Reference Citation Analysis]
146 Elieh Ali Komi D, Shafaghat F, Kovanen PT, Meri S. Mast cells and complement system: Ancient interactions between components of innate immunity. Allergy 2020;75:2818-28. [PMID: 32446274 DOI: 10.1111/all.14413] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
147 Ally M, Magesa P, Luzzatto L. High frequency of acquired aplastic anemia in Tanzania. Am J Hematol 2019;94:E86-8. [PMID: 30592075 DOI: 10.1002/ajh.25388] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
148 Keragala CB, Draxler DF, McQuilten ZK, Medcalf RL. Haemostasis and innate immunity - a complementary relationship: A review of the intricate relationship between coagulation and complement pathways. Br J Haematol 2018;180:782-98. [PMID: 29265338 DOI: 10.1111/bjh.15062] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 9.2] [Reference Citation Analysis]
149 Krishnan S, Sarda S, Kunzweiler C, Wu M, Sundaresan S, Huynh L, Duh MS, Escalante CP. Literature Review of Fatigue Scales and Association with Clinically Meaningful Improvements in Outcomes Among Patients With and Without Paroxysmal Nocturnal Hemoglobinuria. Adv Ther 2022;39:1959-75. [PMID: 35316499 DOI: 10.1007/s12325-022-02111-7] [Reference Citation Analysis]
150 Van Avondt K, Nur E, Zeerleder S. Mechanisms of haemolysis-induced kidney injury. Nat Rev Nephrol 2019;15:671-92. [PMID: 31455889 DOI: 10.1038/s41581-019-0181-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 11.7] [Reference Citation Analysis]
151 Goicoechea de Jorge E, López Lera A, Bayarri-Olmos R, Yebenes H, Lopez-Trascasa M, Rodríguez de Córdoba S. Common and rare genetic variants of complement components in human disease. Mol Immunol 2018;102:42-57. [PMID: 29914697 DOI: 10.1016/j.molimm.2018.06.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
152 Li L, Liu H, Wang H, Liu Z, Chen Y, Li L, Song J, Wang G, Fu R. Abnormal expression and mutation of the RBPJ gene may be involved in CD59- clonal proliferation in paroxysmal nocturnal hemoglobinuria. Exp Ther Med 2019;17:4536-46. [PMID: 31086586 DOI: 10.3892/etm.2019.7475] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
153 Pedersen H, Jensen RK, Jensen JMB, Fox R, Pedersen DV, Olesen HG, Hansen AG, Christiansen D, Mazarakis SMM, Lojek N, Hansen P, Gadeberg TAF, Zarantonello A, Laursen NS, Mollnes TE, Johnson MB, Stevens B, Thiel S, Andersen GR. A Complement C3-Specific Nanobody for Modulation of the Alternative Cascade Identifies the C-Terminal Domain of C3b as Functional in C5 Convertase Activity. J Immunol 2020;205:2287-300. [PMID: 32938727 DOI: 10.4049/jimmunol.2000752] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]